Sanofi Advances Frexalimab With New Phase 3 Study of Subcutaneous vs. IV Dosing in Multiple Sclerosis

TIPRANKS01-09

Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview Sanofi is launching a Phase 3 trial titled “A Randomized, Phas...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602399897?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 00:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602399897","market":"fut","top_or_hot":-1,"title":"Sanofi Advances Frexalimab With New Phase 3 Study of Subcutaneous vs. IV Dosing in Multiple Sclerosis","media":"TIPRANKS","content":"<div>\n<p>Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview Sanofi is launching a Phase 3 trial titled “A Randomized, Phas...</p>\n\n<a href=\"https://www.tipranks.com/news/company-announcements/sanofi-advances-frexalimab-with-new-phase-3-study-of-subcutaneous-vs-iv-dosing-in-multiple-sclerosis?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sanofi Advances Frexalimab With New Phase 3 Study of Subcutaneous vs. IV Dosing in Multiple Sclerosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSanofi Advances Frexalimab With New Phase 3 Study of Subcutaneous vs. IV Dosing in Multiple Sclerosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 00:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/company-announcements/sanofi-advances-frexalimab-with-new-phase-3-study-of-subcutaneous-vs-iv-dosing-in-multiple-sclerosis?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview Sanofi is launching a Phase 3 trial titled “A Randomized, Phas...</p>\n\n<a href=\"https://www.tipranks.com/news/company-announcements/sanofi-advances-frexalimab-with-new-phase-3-study-of-subcutaneous-vs-iv-dosing-in-multiple-sclerosis?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.tipranks.com/news/company-announcements/sanofi-advances-frexalimab-with-new-phase-3-study-of-subcutaneous-vs-iv-dosing-in-multiple-sclerosis?utm_source=itigerup.com&utm_medium=referral","article_id":"2602399897","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sanofi-advances-frexalimab-with-new-phase-3-study-of-subcutaneous-vs-iv-dosing-in-multiple-sclerosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602399897","pubTimestamp":1767890038,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview Sanofi is launching a Phase 3 trial titled “A Randomized, Phas...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SNYNF":"Sanofi"},"translate_title":"赛诺菲通过皮下与静脉给药治疗多发性硬化症的新3期研究推进Frexalimab","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5},"content_text":"Sanofi SA ($SNY) announced an update on their ongoing clinical study. Study Overview Sanofi is launching a Phase 3 trial titled “A Randomized, Phas...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602399897","isCrawlerRequest":true}